Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
US Army
Julphar
Chubb
Daiichi Sankyo
Chinese Patent Office
Cipla
Medtronic
Deloitte

Generated: April 24, 2018

DrugPatentWatch Database Preview

Sunovion Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SUNOVION PHARMS INC, and what generic alternatives to SUNOVION PHARMS INC drugs are available?

SUNOVION PHARMS INC has seven approved drugs.

There are thirty-three US patents protecting SUNOVION PHARMS INC drugs.

There are five hundred patent family members on SUNOVION PHARMS INC drugs in forty-eight countries and forty-four supplementary protection certificates in fourteen countries.

Summary for Sunovion Pharms Inc
International Patents:500
US Patents:33
Tradenames:7
Ingredients:7
NDAs:7

Drugs and US Patents for Sunovion Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-002 Oct 28, 2010 RX Yes No 9,815,827 ➤ Sign Up ➤ Sign Up
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-002 Oct 28, 2010 RX Yes No 9,907,794 ➤ Sign Up Y ➤ Sign Up
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-002 Oct 28, 2010 RX Yes No 5,532,372*PED ➤ Sign Up Y ➤ Sign Up
Sunovion Pharms Inc UTIBRON glycopyrrolate ; indacaterol maleate POWDER;INHALATION 207930-001 Oct 29, 2015 RX Yes Yes 8,956,661 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Sunovion Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-003 Dec 15, 2004 6,864,257*PED ➤ Sign Up
Sunovion Pharms Inc SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 6,521,260 ➤ Sign Up
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-002 Dec 15, 2004 7,381,724*PED ➤ Sign Up
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-001 Dec 15, 2004 6,319,926*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SUNOVION PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 1 mg, 2 mg and 3 mg ➤ Subscribe 2008-12-15
➤ Subscribe Tablets 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg ➤ Subscribe 2014-10-28

Non-Orange Book US Patents for Sunovion Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,744,855 Method of making particles for use in a pharmaceutical composition ➤ Sign Up
7,368,104 Treatment of respiratory diseases ➤ Sign Up
8,436,017 Beta-2-adrenoreceptor agonists ➤ Sign Up
9,566,239 Pharmaceutical formulations for dry powder inhalers ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Sunovion Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1267866/01 Switzerland ➤ Sign Up FORMER REPRESENTATIVE: VOSSIUS AND PARTNER, CH
0140030 00118 Estonia ➤ Sign Up PRODUCT NAME: LURASIDOON;REG NO/DATE: K(2014)2046 (LOPLIK) 27.03.2014
550 Luxembourg ➤ Sign Up PRODUCT NAME: LURASIDONE, FACULTATIVEMENT SOUS FORME DE SA BASE LIBRE OU DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES. FIRST REGISTRATION: 20140327
1884242/01 Switzerland ➤ Sign Up PRODUCT NAME: LURASIDON; REGISTRATION NO/DATE: SWISSMEDIC 62785 12.08.2013
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Citi
UBS
Teva
Daiichi Sankyo
Deloitte
Cipla
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.